A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

• Status: COMPLETED
• Trial end date: 2024-12-18

Summary

For Part 1 of the trial, the main objective is to assess the effect of a single dose of zongertinib on the pharmacokinetics of a single dose of dabigatran-etexilate. For Part 2 of the trial, the main objective is to assess the effect of zongertinib at steady-state on the pharmacokinetics of a single dose of rosuvastatin, metformin and furosemide (administered as a cocktail).

• Phase: PHASE1

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Dabigatran; Furosemide; Metformin; Rosuvastatin Calcium